Sintilimab induced ICIAM in the treatment of advanced HCC: A case report and analysis of research progress

Immune checkpoint inhibitor-associated adverse reactions (irAEs) are a clinical treatment issue that requires additional attention when ICIs have significant survival benefits in patients with advanced hepatocellular carcinoma (HCC). Among them, ICIs-associated myocarditis (ICIAM) is a kind of sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Hongxiang, Wen, Zhijian, Liu, Bin, Chen, Hongbiao, Lin, Qian, Chen, Zhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458972/
https://www.ncbi.nlm.nih.gov/pubmed/36091070
http://dx.doi.org/10.3389/fimmu.2022.995121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9458972/
https://www.ncbi.nlm.nih.gov/pubmed/36091070
http://dx.doi.org/10.3389/fimmu.2022.995121

Ejemplares similares